Document is current
Any future updates will be listed below
-
Authors
Maher, Toby M https://orcid.org/0000-0001-7192-9149
Kreuter, Michael
Lederer, David J
Brown, Kevin K
Wuyts, Wim
Verbruggen, Nadia
Stutvoet, Simone
Fieuw, Ann
Ford, Paul
Abi-Saab, Walid
Wijsenbeek, Marlies
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03711162 at ClinicalTrials.govnct03733444 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 2 study design and analysis approach for BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosis
https://doi.org/10.1136/bmjresp-2024-003038
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
https://doi.org/10.1136/bmjresp-2019-000422
nct03711162 at ClinicalTrials.govDocuments that mention this clinical trial
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
https://doi.org/10.1136/bmjresp-2019-000422
nct03733444 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 2 study design and analysis approach for BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosis
https://doi.org/10.1136/bmjresp-2024-003038
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
https://doi.org/10.1136/bmjresp-2019-000422
Documents that mention this clinical trial
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
https://doi.org/10.1136/bmjresp-2019-000422
-
Funding
Funding for this research was provided by:
Galapagos NV
